Abstract
There is great demand for lower-cost biological drugs: commercial and
regulatory developments will make biosimilars and follow-on biologics a
success - our new report explains how.
Revenues for biologic drugs reached approximately $125bn in 2008. Patents on
most current biologics have expired or will expire during the period 2009 to
2024. In addition, there is mounting pressure from governments, insurers and
patients' groups to reduce costs of pharmaceuticals. Biologic drugs - noted as
some of the most-expensive medicines - are major targets for cost savings. The
developments facilitating follow-on biologics are gaining momentum, with
significant commercial opportunities emerging - as our new report explains.
Recently Merck & Co. established a new biosimilar (follow-on biologic or
biogeneric) development division; other major pharmaceutical companies plan to
follow suit. In March 2009, three new bills on follow-on biologic legislation
were introduced to the US Congress. Biosimilars are entering an important
period of development. Is your company prepared for the opportunities and
threats this will create? The new visiongain report - Biosimilars and
Follow-On Biologics: The Global Outlook 2009-2024 - provides you with
essential information to understand this rapidly-emerging market.
This report predicts how the biosimilar market will evolve from 2009 to 2024.
We indentify and discuss the biosimilar drugs and manufacturers that will
achieve commercial success during the coming fifteen years.
Biologic drug classes covered in this report include:
- Growth hormones
- Insulin
- Erythropoietin
- Colony stimulating factors and interleukin-2 drugs
- Interferons
- Monoclonal antibodies
- Fusion proteins
The biosimilar prospects for each class are examined, biosimilar targets
identified and market forecasts to 2024 provided, with extensive supporting
information.
Comprehensive analysis of the global market
Using a wealth of research - including detailed sales forecasting, interviews
with key opinion leaders and examination of policy documents, reports,
industry news, filings and commercial databases - our new study forecasts how
the biosimilar market will progress from 2009 to 2024.
Why you should buy Biosimilars and Follow-On Biologics: The Global Outlook 2009-2024
By obtaining your copy of this report, you will benefit from:
- Forecasts for the world biosimilar market, leading biosimilar drug types
and leading national markets
- Identification of biologic drugs with potential for commercial biosimilar
development
- Original interviews with biosimilar industry experts, who discuss the
present and future of the sector
- Examination of the driving forces, restraints, competition and
opportunities facing commercial stakeholders in the biologic and biosimilar
sectors
- Analysis of biosimilar legislation and regulatory guidance in the US,
Europe and Japan - with current and emerging trends discussed
- Analysis of the biosimilar pipeline - find out what and who will be the
leading biosimilar players over the next fifteen years
- Prediction of where the market is heading - both technologically and
commercially - from the present onwards.
The complexity of biologic drugs has retarded development of regulatory
frameworks for approval of biosimilars in many countries. The EU was the first
major regulatory authority to adopt a procedure allowing regulatory approval
of biosimilar medicines. The US awaits a similar legal and regulatory
framework. Currently, the FDA can only approve a restricted number of simpler
‘follow-on protein products' . Approval of more-complex biosimilars will
necessitate a formal legal and regulatory pathway in the US. Visiongain
believes that the US Congress will approve a biosimilar bill within a few
years. In this report, we predict the emergence of biosimilar products in the
US, in addition to developments in other major markets during the years ahead.
| 
View Cart
